Tesamorelin vs. Ipamorelin: One Is FDA-Approved, One Has Never Been

Both raise the body’s own growth hormone rather than supplying it, and both do it by signalling the pituitary. But they arrive at the pituitary through different doors, and that difference is real rather than marketing.

Tesamorelin is a GHRH analogue

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It binds the GHRH receptor — the same receptor the body’s own GHRH uses — and prompts the pituitary to release growth hormone in a pattern that follows the body’s existing rhythm. Sermorelin works on this same receptor, which is why those two are the closer pair; we cover that on tesamorelin vs. sermorelin.

Ipamorelin is a ghrelin-receptor secretagogue

Ipamorelin does not act on the GHRH receptor at all. It binds the ghrelin receptor — the growth hormone secretagogue receptor — which is a separate signalling pathway that also ends in growth hormone release. Compounds in this class are often described as “GHRPs” or secretagogues. Our ipamorelin page covers the class in more detail.

So the two are not weaker and stronger versions of one another. They are different drug classes acting on different receptors, which is also the reason the question of combining them comes up so often.

This is the question people most often arrive with, and the honest answer is that the two compounds are not on equal footing here.

Tesamorelin has a demonstrated effect on visceral abdominal fat — measured by CT, in a defined patient population, in the trials that supported its approval. That is the indication it holds.

Ipamorelin has no approved indication for fat reduction, and no comparable body of evidence showing it reduces visceral fat in adults. Pages that present the two as alternative routes to the same result are describing a mechanism in theory, not a demonstrated outcome.

There is also a distinction worth understanding before either compound enters the conversation: visceral fat and subcutaneous fat are not the same tissue. Visceral fat sits deep in the abdomen around the organs. Subcutaneous fat is the layer under the skin. A compound that acts on one is not automatically acting on the other, and neither is the same as losing weight. Most disappointment with these medicines traces back to that confusion.

This is one of the most common questions asked about the pair, and it is usually answered with a mechanism story: two different receptors, so the effects should add up. That reasoning is not unreasonable on paper.

What it leaves out is the regulatory reality. No combined tesamorelin-ipamorelin product holds FDA approval. A combined vial is a compounded preparation, which means it has not been evaluated by the FDA for safety, efficacy or manufacturing quality — and combining two compounds does not inherit the approval that one of them holds on its own.

This is not a hypothetical concern. The FDA has issued a warning letter to a seller marketing a combination product under the brand name BIMORELIN, described in the agency’s own letter as containing Tesamorelin (10mg) and Ipamorelin (3mg). That is a matter of public record, and it is worth knowing before a blend is presented as a routine option.

The practical takeaway: a blend is not a stronger version of an approved medicine. It is two compounds — one approved for a narrow indication, one never approved at all — in a preparation no regulator has reviewed. If a clinician recommends one, that reasoning should be explained and documented, not assumed.

That depends on what problem you are actually trying to solve, and for one of these compounds there is a defined answer.

If the problem is excess visceral abdominal fat in an adult with HIV-associated lipodystrophy, tesamorelin is the compound with an approved indication, a labeled adult dose and registration-trial data behind it. That is a narrow population, and it is the only population the approval covers.

If the problem is general recovery, sleep quality, anti-aging or body composition in an otherwise healthy adult, then neither compound has an approved indication for it. That does not automatically make either one inappropriate — physicians prescribe off-label and compounded medicines for considered reasons — but it does mean the decision rests on clinical judgment rather than on an approval, and it should be made that way, out loud, with the trade-offs named.

If the peptide you are actually weighing is sermorelin, two companion pages cover those pairings: tesamorelin vs. sermorelin and sermorelin vs. ipamorelin.